Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma

Authors: Liangliang Xu, Peng Wang, Li Li, Lian Li, Yang Huang, Yanfang Zhang, Xiaobo Zheng, Pengsheng Yi, Ming Zhang, Mingqing Xu

Published in: Molecular Cancer | Issue 1/2023

Login to get access

Abstract

Background

Vascular invasion is a major route for intrahepatic and distant metastasis in hepatocellular carcinoma (HCC) and is a strong negative prognostic factor. Circular RNAs (circRNAs) play important roles in tumorigenesis and metastasis. However, the regulatory functions and underlying mechanisms of circRNAs in the development of vascular invasion in HCC are largely unknown.

Methods

High throughput sequencing was used to screen dysregulated circRNAs in portal vein tumor thrombosis (PVTT) tissues. The biological functions of candidate circRNAs in the migration, vascular invasion, and metastasis of HCC cells were examined in vitro and in vivo. To explore the underlying mechanisms, RNA sequencing, MS2-tagged RNA affinity purification, mass spectrometry, and RNA immunoprecipitation assays were performed.

Results

circRNA sequencing followed by quantitative real-time PCR (qRT-PCR) revealed that circRNA pleckstrin and Sect. 7 domain containing 3 (circPSD3) was significantly downregulated in PVTT tissues. Decreased circPSD3 expression in HCC tissues was associated with unfavourable characteristics and predicted poor prognosis in HCC. TAR DNA-binding protein 43 (TDP43) inhibited the biogenesis of circPSD3 by interacting with the downstream intron of pre-PSD3. circPSD3 inhibited the intrahepatic vascular invasion and metastasis of HCC cells in vitro and in vivo. Serpin family B member 2 (SERPINB2), an endogenous bona fide inhibitor of the urokinase-type plasminogen activator (uPA) system, is the downstream target of circPSD3. Mechanistically, circPSD3 interacts with histone deacetylase 1 (HDAC1) to sequester it in the cytoplasm, attenuating the inhibitory effect of HDAC1 on the transcription of SERPINB2. In vitro and in vivo studies demonstrated that circPSD3 is a promising inhibitor of the uPA system.

Conclusions

circPSD3 is an essential regulator of vascular invasion and metastasis in HCC and may serve as a prognostic biomarker and therapeutic target.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer. Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
2.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.PubMedCrossRef
3.
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and underlying etiologies from 1990 to 2015 at the Global, Regional, and National Level: results from the global burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–91.PubMedPubMedCentralCrossRef
4.
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV patients treated with Direct-Acting Antiviral agents. Gastroenterology. 2017;153:996–1005e1.PubMedCrossRef
5.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty Liver Disease demonstrates an exponential increase in burden of Disease. Hepatology. 2018;67:123–33.PubMedCrossRef
6.
7.
Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zhong JH, Li LQ. New evidence and perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017;5:169–76.PubMedPubMedCentral
8.
Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer. 2020;9:28–40.PubMedCrossRef
9.
Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998;21:386–91.PubMedCrossRef
10.
Huo L, Wei W, Yan Z, Lei Z, Xie Y, Gong R, Huang S, Jia N, Xia Y. Short-term and long-term outcomes of liver resection for HCC patients with portal vein Tumor thrombus. Cell Biosci. 2019;9:23.PubMedPubMedCentralCrossRef
11.
Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–43.PubMedCrossRef
12.
Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20:675–91.PubMedCrossRef
13.
Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185:2390.PubMedCrossRef
14.
Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475–90.PubMedCrossRef
15.
16.
Xu L, Zhang M, Zheng X, Yi P, Lan C, Xu M. The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143:17–27.PubMedCrossRef
17.
Xu L, Feng X, Hao X, Wang P, Zhang Y, Zheng X, et al. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38:98.PubMedPubMedCentralCrossRef
18.
Hu ZQ, Zhou SL, Li J, Zhou ZJ, Wang PC, Xin HY, et al. Circular RNA sequencing identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis. Hepatology. 2020;72:906–22.PubMedCrossRef
19.
Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP. Burroughs AK A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–39.PubMedCrossRef
20.
Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Guanghui D, Wenming C, Peijun W. Yuxiang Z Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the Tumor thrombi in the portal vein. Hepatogastroenterology. 2007;54:499–502.PubMed
21.
Zhang H, Ye J, Weng X, Liu F, He L, Zhou D, Liu Y. Comparative transcriptome analysis reveals that the extracellular matrix receptor interaction contributes to the venous metastases of hepatocellular carcinoma. Cancer Genet. 2015;208:482–91.PubMedCrossRef
22.
Liu S, Guo W, Shi J, Li N, Yu X, Xue J, et al. MicroRNA-135a contributes to the development of portal vein Tumor thrombus by promoting Metastasis in hepatocellular carcinoma. J Hepatol. 2012;56:389–96.PubMedCrossRef
23.
24.
Xu L, Wang P, Feng X, Tang J, Li L, Zheng X, et al. SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and Metastasis of hepatocellular carcinoma. Clin Sci (Lond). 2019;133:2085–105.PubMedCrossRef
25.
Vinci M, Box C, Eccles SA. Three-dimensional (3D) Tumor spheroid invasion assay. J Vis Exp. 2015;e52686.
26.
Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, et al. Advances in establishment and analysis of three-dimensional Tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012;10:29.PubMedPubMedCentralCrossRef
27.
Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen. 2006;11:922–32.PubMedCrossRef
28.
Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125–34.PubMedCrossRef
29.
Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–66.PubMedCrossRef
30.
Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10:170–7.PubMedCrossRef
31.
Doke AA, Jha SK, Shapeshifter. TDP-43: molecular mechanism of structural polymorphism, aggregation, phase separation and their modulators. Biophys Chem. 2023;295:106972.PubMedCrossRef
32.
Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, et al. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013;58:182–91.PubMedCrossRef
33.
Guo F, Wang H, Jiang M, Yang Q, Xiang Q, Zhou H, et al. TDP-43 induces EMT and promotes hepatocellular carcinoma Metastasis via activating Wnt/β-catenin signaling pathway. Am J Cancer Res. 2020;10:3285–301.PubMedPubMedCentral
34.
Liu BW, Wang XY, Cao JL, Chen LL, Wang YL, Zhao BQ, Zhou J. Shen ZF TDP-43 upregulates lipid metabolism modulator ABHD2 to suppress apoptosis in hepatocellular carcinoma. Commun Biol. 2022;5:816.PubMedPubMedCentralCrossRef
35.
Cochran BJ, Gunawardhana LP, Vine KL, Lee JA, Lobov S, Ranson M. The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity. BMC Biotechnol. 2009;9:43.PubMedPubMedCentralCrossRef
36.
Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer. 2008;8:535–45.PubMedCrossRef
37.
Su SC, Lin CW, Yang WE, Fan WL, Yang SF. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets. 2016;20:551–66.PubMedCrossRef
38.
Zhou L, Jin Y, Cui QC, Jin KM, Zhou WX, Xing BC. Low expression of PAI-2 as a novel marker of portal vein Tumor Thrombosis and poor prognosis in hepatocellular carcinoma. World J Surg. 2013;37:608–13.PubMedCrossRef
39.
Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and – 2 in hepatocellular carcinoma. Pathol Int. 2000;50:392–7.PubMedCrossRef
40.
De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 1998;58:2234–9.PubMed
41.
Du J, Lan T, Liao H, Feng X, Chen X, Liao W, et al. CircNFIB inhibits Tumor growth and Metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma. Mol Cancer. 2022;21:18.PubMedPubMedCentralCrossRef
42.
Hong X, Li Q, Li J, Chen K, He Q, Zhao Y, et al. CircIPO7 promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by facilitating YBX1 Nuclear localization. Clin Cancer Res. 2022;28:4521–35.PubMedCrossRef
43.
Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell. 2004;117:721–33.PubMedCrossRef
44.
Macaluso M, Montanari M, Marshall CM, Gambone AJ, Tosi GM, Giordano A, Massaro-Giordano M. Cytoplasmic and nuclear interaction between rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells. Cell Death Differ. 2006;13:1515–22.PubMedCrossRef
45.
Pucci S, Zonetti MJ, Fisco T, Polidoro C, Bocchinfuso G, Palleschi A, Novelli G, Spagnoli LG. Mazzarelli P carnitine palmitoyl transferase-1A (CPT1A): a new Tumor specific target in human Breast cancer. Oncotarget. 2016;7:19982–96.PubMedPubMedCentralCrossRef
46.
Mekkawy AH, Pourgholami MH. Morris DL involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev. 2014;34:918–56.PubMedCrossRef
47.
Xie X, Li H, Gao C, Lai Y, Liang J, Chen Z, et al. Downregulation of circular RNA circPSD3 promotes Metastasis by modulating FBXW7 expression in Clear Cell Renal Cell Carcinoma. J Oncol. 2022;2022:5084631.PubMedPubMedCentralCrossRef
48.
Zhu J, Wang Y, Yang C, Feng Z, Huang Y, Liu P, Chen F, Deng Z. circ-PSD3 promoted proliferation and invasion of papillary thyroid cancer cells via regulating the miR-7-5p/METTL7B axis. J Recept Signal Transduct Res. 2022;42:251–60.PubMedCrossRef
49.
Bu FT, Zhu Y, Chen X, Wang A, Zhang YF, You HM, et al. Circular RNA circPSD3 alleviates hepatic fibrogenesis by regulating the miR-92b-3p/Smad7 axis. Mol Ther Nucleic Acids. 2021;23:847–62.PubMedPubMedCentralCrossRef
50.
Chen TC, Tallo-Parra M, Cao QM, Kadener S, Böttcher R, Pérez-Vilaró G, et al. Host-derived circular RNAs display proviral activities in Hepatitis C virus-infected cells. PLoS Pathog. 2020;16:e1008346.PubMedPubMedCentralCrossRef
51.
Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ, Sun SH, Yang F. Zhou WP Circular RNA cSMARCA5 inhibits growth and Metastasis in hepatocellular carcinoma. J Hepatol. 2018;68:1214–27.PubMedCrossRef
52.
Chioccarelli T, Falco G, Cappetta D, De Angelis A, Roberto L, Addeo M, et al. FUS driven circCNOT6L biogenesis in mouse and human spermatozoa supports zygote development. Cell Mol Life Sci. 2021;79:50.PubMedPubMedCentralCrossRef
53.
Wang R, Zhang S, Chen X, Li N, Li J, Jia R, Pan Y, Liang H. EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes Glioblastoma Multiforme cell tumorigenesis. Mol Cancer. 2018;17:166.PubMedPubMedCentralCrossRef
54.
Liu Y, Song J, Zhang H, Liao Z, Liu F, Su C, et al. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway. J Exp Clin Cancer Res. 2022;41:164.PubMedCrossRef
55.
de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative Diseases. J Neurol Neurosurg Psychiatry. 2020;92:86–95.PubMedCrossRef
56.
Guo L, Ke H, Zhang H, Zou L, Yang Q, Lu X, Zhao L, Jiao B. TDP43 promotes stemness of Breast cancer stem cells through CD44 variant splicing isoforms. Cell Death Dis. 2022;13:428.PubMedPubMedCentralCrossRef
57.
Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, et al. Loss of TDP43 inhibits progression of triple-negative Breast cancer in coordination with SRSF3. Proc Natl Acad Sci U S A. 2018;115:E3426–e35.PubMedPubMedCentralCrossRef
58.
Chen X, Fan Z, McGee W, Chen M, Kong R, Wen P, et al. TDP-43 regulates cancer-associated microRNAs. Protein Cell. 2018;9:848–66.PubMedCrossRef
59.
Zeng Q, Cao K, Liu R, Huang J, Xia K, Tang J, et al. Identification of TDP-43 as an oncogene in Melanoma and its function during Melanoma pathogenesis. Cancer Biol Ther. 2017;18:8–15.PubMedCrossRef
60.
Guo SK, Nan F, Liu CX, Yang L, Chen LL. Mapping circular RNA structures in living cells by SHAPE-MaP. Methods. 2021;196:47–55.PubMedCrossRef
61.
Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, et al. Structure and degradation of circular RNAs regulate PKR activation in Innate Immunity. Cell. 2019;177:865–80e21.PubMedCrossRef
62.
Ler SY, Leung CH, Khin LW, Lu GD, Salto-Tellez M, Hartman M, Iau PT, Yap CT. Hooi SC HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a southeast Asian population. Oncol Rep. 2015;34:2238–50.PubMedPubMedCentralCrossRef
63.
Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 2007;72:69–74.PubMedCrossRef
64.
Zhao B, Ke K, Wang Y, Wang F, Shi Y, Zheng X, Yang X, Liu X, Liu J. HIF-1α and HDAC1 mediated regulation of FAM99A-miR92a signaling contributes to hypoxia induced HCC Metastasis. Signal Transduct Target Ther. 2020;5:118.PubMedPubMedCentralCrossRef
65.
Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M. Rømer J Plasminogen activation and cancer. Thromb Haemost. 2005;93:676–81.PubMedCrossRef
66.
Baldini E, Sorrenti S, D’Armiento E, Di Matteo FM, Catania A, Ulisse S. The urokinase plasminogen activating system in thyroid cancer: clinical implications. G Chir. 2012;33:305–10.PubMed
67.
O’Rourke J, Jiang X, Hao Z, Cone RE. Hand AR distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. J Neurosci Res. 2005;79:727–33.PubMedCrossRef
68.
Ranson M, Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003;8:294–304.CrossRef
69.
Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des. 2003;9:1499–528.PubMedCrossRef
70.
Behrendt N, List K, Andreasen PA. Danø K the pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J. 2003;371:277–87.PubMedPubMedCentralCrossRef
71.
72.
Kruithof EK, Baker MS. Bunn CL Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 1995;86:4007–24.PubMedCrossRef
73.
Al-Ejeh F, Croucher D, Ranson M. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp Cell Res. 2004;297:259–71.PubMedCrossRef
74.
Lillis AP, Mikhailenko I, Strickland DK. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost. 2005;3:1884–93.PubMedCrossRef
75.
Tao P, Gao L, Li H, Wang B, Li X, Zhang Y, Chen H. Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: a protocol for systematic review and meta analysis. Med (Baltim). 2020;99:e23841.CrossRef
76.
Salvi A, Arici B, De Petro G, Barlati S. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther. 2004;3:671–8.PubMedCrossRef
77.
Niu FY, Jin C, Ma L, Shi YX, Li XS, Jiang P, Gao S, Lin JR. Song Y urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma. J Gastrointest Oncol. 2021;12:1851–59.PubMedPubMedCentralCrossRef
78.
Ulisse S, Baldini E, Sorrenti S, D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9:32–71.PubMedCrossRef
79.
Mekkawy AH, Morris DL. Pourgholami MH Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009;5:1487–99.PubMedCrossRef
80.
Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S. De Petro G effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer. 2013;12:162.PubMedPubMedCentralCrossRef
81.
Fernández-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sánchez-Prieto R, Fabra A. Ramón YCS Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a Tumor suppressor effect. Int J Oncol. 2006;28:143–8.PubMed
82.
Guan M, Jiang H, Xu C, Xu R, Chen Z, Lu Y. Adenovirus-mediated PEDF expression inhibits Prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol Ther. 2007;6:419–25.PubMedCrossRef
83.
Shimizu T, Sato K, Suzuki T, Tachibana K, Takeda K. Induction of plasminogen activator inhibitor-2 is associated with suppression of invasive activity in TPA-mediated differentiation of human Prostate cancer cells. Biochem Biophys Res Commun. 2003;309:267–71.PubMedCrossRef
84.
Litke JL, Jaffrey SR. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat Biotechnol. 2019;37:667–75.PubMedCentralCrossRef
85.
Jost I, Shalamova LA, Gerresheim GK, Niepmann M, Bindereif A, Rossbach O. Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges. RNA Biol. 2018;15:1032–39.PubMedPubMedCentral
86.
Schreiner S, Didio A, Hung LH, Bindereif A. Design and application of circular RNAs with protein-sponge function. Nucleic Acids Res. 2020;48:12326–35.PubMedPubMedCentralCrossRef
Metadata
Title
circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma
Authors
Liangliang Xu
Peng Wang
Li Li
Lian Li
Yang Huang
Yanfang Zhang
Xiaobo Zheng
Pengsheng Yi
Ming Zhang
Mingqing Xu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2023
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-023-01882-z

Other articles of this Issue 1/2023

Molecular Cancer 1/2023 Go to the issue

Review

Emerging roles of tRNA-derived fragments in cancer

Correction

Correction: circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion

Retraction Note

Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer

Research

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Correspondence

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies

Correspondence

Unveiling the hidden AP-1: revealing the crucial role of AP-1 in ccRCC at single-cell resolution
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits